Search results for "Liver function"

showing 10 items of 176 documents

Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection.

2008

OBJECTIVES: Metabolic factors may affect the course of chronic hepatitis C (CHC). Insulin resistance (IR) determines steatosis, but its direct role in affecting progression of hepatic fibrosis is less clear. We aimed to assess whether increasing degrees of IR, up to overt diabetes, are linked to steatosis and higher stages of fibrosis in patients with CHC resulting from genotype 1 HCV (G1-HCV). METHODS: Two hundred one consecutive patients with G1-HCV infection were evaluated by liver biopsy and anthropometric and metabolic measurements, including IR, by the homeostasis model assessment (HOMA). Nondiabetic patients were defined as insulin resistant if HOMA-IR was >2.7. All biopsies were …

Liver Cirrhosismedicine.medical_specialtyGenotypeBiopsyHepacivirusSettore MED/08 - Anatomia PatologicaGastroenterologyCohort StudiesInsulin resistanceLiver Function TestsFibrosisRisk FactorsInternal medicineDiabetes mellitusGenotypeBiopsymedicineHumansSettore MED/12 - GastroenterologiaHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyvirus diseasesHepatitis CHepatitis C Chronicmedicine.diseasePrognosisdigestive system diseasesFatty LiverEndocrinologyCross-Sectional StudiesDiabetes Mellitus Type 2Liverhcv fibrosis IR liverRNA ViralViral diseaseInsulin ResistancebusinessLiver function testsThe American journal of gastroenterology
researchProduct

Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?

2014

Long-lasting HBV-DNA suppression is considered to be the best surrogate end-point of antiviral therapy in patients with hepatitis B virus (HBV) related chronic hepatitis or cirrhosis, and it is a prerequisite to prevent liver-related complications and improve survival. Treatment with oral antiviral drugs in patients with HBV cirrhosis is effective in restoring liver function and improving survival even in those with decompensated cirrhosis. These agents are generally well-tolerated for long-term treatment, and several evidences have demonstrated that they are able to reverse liver fibrosis and prevent the occurrence of HCC.

Liver Cirrhosismedicine.medical_specialtyHepatitis B virusCirrhosisCarcinoma HepatocellularGuanineLiver fibrosisOrganophosphonatesAdministration Oralmedicine.disease_causeGastroenterologyAntiviral AgentsFibrosisInternal medicinemedicineHumansIn patientTenofovirHepatitis B virusTelbivudineHepatologybusiness.industryAdeninecirrhosisLiver NeoplasmsAntiviral therapyNucleosidesmedicine.diseaseHepatitis BFibrosisdigestive system diseasesLamivudineHepatocellular carcinomaLiver functionbusinessThymidine
researchProduct

Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts.

2012

A disseminated model of non-Hodgkin's lymphoma with prevalent liver metastasis was generated by intraperitoneal (i.p.) injection of EBV(+) B lymphoblastoid SKW6.4 in nude-SCID mice. The survival of SKW6.4 xenografts (median survival = 27 days) was significantly improved when hyaluronan scaffolds embedded with mesenchimal stem cells (MSC) were implanted in the abdominal area 4 days after SKW6.4 injection (median survival = 39.5 days). Mice implanted with MSC showed a significant improvement of hepatic functionality in lymphoma xenografts, as demonstrated by measurement of serum ALT/AST levels. Co-culture of MSC with lymphoma cells enhanced the release of hepatocyte growth factor (HGF) by MSC…

Liver functionality. Lymphoma-bearing xenograftsPathologymedicine.medical_specialtyTime FactorsCell SurvivalMice NudeCell CommunicationMice SCIDMesenchymal Stem Cell Transplantationlymphoma.Mesenchymal stem cells; hepato-protective; lymphoma.Metastasischemistry.chemical_compoundMicehemic and lymphatic diseasesCell Line Tumorhepato-protectiveHyaluronic acidMedicineAnimalsHumansPharmacology (medical)Aspartate AminotransferasesHyaluronic AcidMesenchymal stem cellPharmacologyMesenchymal stem cells; Liver functionality. Lymphoma-bearing xenograftsTissue Scaffoldsbusiness.industryHepatocyte Growth FactorLymphoblastLymphoma Non-HodgkinMesenchymal stem cellLiver NeoplasmsAlanine TransaminaseMesenchymal Stem Cellsmedicine.diseaseXenograft Model Antitumor AssaysCoculture TechniquesLymphomaOncologychemistryLiverCell cultureHepatocyte growth factorStem cellbusinessBiomarkersmedicine.drugInvestigational new drugs
researchProduct

Liver injury, SARS‐COV‐2 infection and COVID‐19: What physicians should really know?

2021

Abstract Background & Aims Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) is responsible for coronavirus disease 2019 (COVID‐19), which in males, especially in advanced age, can sometimes evolve into acute respiratory distress syndrome. In addition, mild to moderate alterations in liver function tests (LFTs) have been reported in the worst affected patients. Our review aims to analyse data on the incidence and prognostic value of LFT alterations, the underlying mechanisms and the management of pre‐existing liver disease in COVID‐19 affected patients. Methods We searched available literature through online PubMed database using terms as “SARS‐CoV‐2,” “Liver damage,” “Liver Func…

Liver injurymedicine.medical_specialtyCirrhosismedicine.diagnostic_testbusiness.industryMortality rateIncidence (epidemiology)Review Articlemedicine.diseaseSARS‐CoV‐2PneumoniaLiver diseaseCOVID‐19Internal medicinemedicineLiver Function tests (LTFs)businessLiver function testsliver injuryCohort studyGastroHep
researchProduct

Akutes Leberversagen – Internistische Sicht

2006

Acute liver failure is a rare disease that can cause death in the majority of untreated cases. Sudden loss of liver function in the absence of a preexisting liver disease is considered the true form and has to be distinguished from impaired function following exacerbation of an underlying liver disease (acute or chronic failure). Common causes include acute viral hepatitis, drug induced liver injury (DILI) and toxins. The loss of the excretory and synthetic function of the liver marks the clinical presentation and results in icterus, coagulopathy and encephalopathy. Additionally impairment of renal function and sepsis occur and contribute to the high mortality of this disease. The activatio…

Liver injurymedicine.medical_specialtyPathologyExacerbationmedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentEncephalopathyGeneral MedicineLiver transplantationmedicine.diseaseGastroenterologyLiver diseaseInternal medicinemedicineCoagulopathyLiver functionbusinessLiver function testsPraxis
researchProduct

The effectiveness and applicability of different lifestyle interventions for enhancing wellbeing : the study design for a randomized controlled trial…

2014

Background: Obesity and stress are among the most common lifestyle-related health problems. Most of the current disease prevention and management models are not satisfactorily cost-effective and hardly reach those who need them the most. Therefore, novel evidence-based controlled interventions are necessary to evaluate models for prevention and treatment based on self-management. This randomized controlled trial examines the effectiveness, applicability, and acceptability of different lifestyle interventions with individuals having symptoms of metabolic syndrome and psychological distress. The offered interventions are based on cognitive behavioral approaches, and are designed for enhancing…

Male050103 clinical psychologyMindfulnessmedicine.medical_treatmentHealth BehaviorhyvinvointiPsychological interventionAcceptance and commitment therapylaw.inventionStudy Protocol0302 clinical medicineRandomized controlled trialRisk Factorslawmobiilisovellukset030212 general & internal medicineelämäntapaCOMMITMENT THERAPYMetabolic SyndromeWeb-based intervention05 social sciencesylipainoteknologia-avusteinen interventioCOGNITIVE-BEHAVIOR THERAPY3. Good healthCognitive behavioral therapyResearch Designkognitiivinen käyttäytymisterapia/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemaleHEALTHmedicine.medical_specialty515 Psychologyhyväksymis- ja omistautumisterapiaeducationWell-beingWeb based interventionMobile applicationStress03 medical and health sciencesSDG 3 - Good Health and Well-beingmedicineHumans0501 psychology and cognitive sciencesObesityAcceptance and Commitment TherapySELF-MANAGEMENTINTERNETExerciseLife StyleEATING COMPETENCE MODELPsykologi (exklusive tillämpad psykologi)business.industryPublic Health Environmental and Occupational HealthACCEPTANCEstressiSMOKING-CESSATIONLifestyleDietCognitive behavioral therapySelf CarePsychology (excluding Applied Psychology)Clinical trialPHYSICAL-ACTIVITYPSYCHOMETRIC PROPERTIESTechnology-aided interventionsCognitive therapyPhysical therapylihavuusLiver function3111 BiomedicinebusinessRisk Reduction BehaviorTechnology aided interventionsStress PsychologicalProgram Evaluation
researchProduct

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 tria…

2019

© 2019 Elsevier Ltd. All rights reserved.

MaleBiopsyClinical Trial Phase IIIAdministration Oral030204 cardiovascular system & hematologyChronic liver diseaseSettore MED/04Biomarkers/analysisGastroenterologychemistry.chemical_compound0302 clinical medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D013485Liver Function TestsNon-alcoholic Fatty Liver DiseaseClinical endpointMedicine030212 general & internal medicine610 Medicine & healthChenodeoxycholic Acid/administration & dosageeducation.field_of_studyLiver Function TestResearch Support Non-U.S. Gov'tFatty liverObeticholic acidNASH OBETICHOLIC ACIDGeneral Medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D052061Middle AgedMulticenter Study/dk/atira/pure/researchoutput/pubmedpublicationtype/D016448Randomized Controlled TrialAdministrationFemale/dk/atira/pure/researchoutput/pubmedpublicationtype/D016449Administration Oral; Biomarkers; Biopsy; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver DiseaseHumanOralmedicine.medical_specialtyPopulationPlaceboChenodeoxycholic Acid03 medical and health sciencesResearch Support N.I.H. ExtramuralDouble-Blind MethodInternal medicineJournal ArticleHumans/dk/atira/pure/researchoutput/pubmedpublicationtype/D017428educationIntention-to-treat analysisbusiness.industryBiomarkerInterim analysismedicine.diseaseNon-alcoholic Fatty Liver Disease/drug therapychemistryHuman medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D016428businessBiomarkersAdministration; Oral; Biomarkers; Biopsy; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver Disease
researchProduct

Trends in net survival from liver cancer in six European Latin countries: results from the SUDCAN population-based study

2016

Liver cancer represents a major clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from liver cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and provide trends in net survival and dynamics of excess mortality rates (EMRs) up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Results are reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. These tren…

MaleCancer ResearchDatabases FactualEpidemiologyTrends in survival0302 clinical medicineBelgiumCancer screeningMedicineCancer registries030212 general & internal medicineRegistriesYoung adultAged 80 and overmedicine.diagnostic_testMortality rateMedical recordLiver NeoplasmsMiddle Aged3. Good healthCancer registries; Europe; Excess mortality rate; Liver cancer; Net survival; Trends in survival;Survival RateEuropeOncologyItaly030220 oncology & carcinogenesisPopulation SurveillanceFemaleFranceLiver cancerLiver cancerSwitzerlandAdultAdolescentSocio-culturale03 medical and health sciencesYoung AdultNet survivalHumansAgedPortugalExcess mortality ratebusiness.industryPublic Health Environmental and Occupational Healthmedicine.diseaseCancer registrySpainLiver functionbusinessLiver function testsDemography
researchProduct

Acute and chronic hepatitis in childhood leukemia: a multicentric study from the Italian Pediatric Cooperative Group for Therapy of Acute Leukemia (A…

1985

The incidence of acute and chronic liver damage and its relation to hepatitis B virus (HBV) infection was evaluated in 164 consecutive children with acute leukemia seen in ten Italian hemato-pediatric units. Thirteen out of 164 children (7.9%) had acute hepatitis (AH) during treatment, while 8/90 (8.8%) showed an acute exacerbation of liver damage within 6 months after therapy withdrawal. Seven of the 13 children with AH while on therapy were HBsAg positive. In 12/13 cases, liver disease progressed to chronicity. Five of eight children who developed AH after completion of treatment were HBsAg positive. Eighty-nine patients (54.2%) developed biochemical evidence of chronic hepatitis during t…

MaleCancer Researchmedicine.medical_specialtyHBsAgChildhood leukemiaExacerbationAdolescentmedicine.disease_causeGastroenterologyacute hepatitisHepatitisLiver diseasechronic hepatitiLiver Function TestsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChildHepatitis B virusAcute leukemiaHepatitis B Surface AntigensLeukemiabusiness.industryLiver cellacute hepatitichildhood leukemiavirus diseasesInfantmedicine.diseaseacute hepatitis; chronic hepatitis; childhood leukemiaHepatitis BLeukemia LymphoidLeukemiaAcute and chronic hepatitis; childhood leukemia; multicentric study from AIEOPOncologyItalyChild PreschoolPediatrics Perinatology and Child HealthImmunologyAcute DiseaseFemalechronic hepatitisChemical and Drug Induced Liver InjurybusinessMedical and pediatric oncology
researchProduct

Alpha-Interferon Treatment in HBeAg Positive Children with Chronic Hepatitis B and Associated Hepatitis D

1998

The main problem of children with HBeAg positive hepatitis B and associated hepatitis D is progression to liver cirrhosis with decompensation of liver function and need for liver replacement therapy within 15-20 years after infection. To determine whether interferon-alpha (IFN-alpha) therapy has a positive effect on HBV replication and inflammatory activity, we evaluated clinical and serological data of 8 children treated with IFN-alpha and 6 historic control patients without treatment. 4 of the nontreated patients seroconverted from HBeAg to anti-HBe between 7 to 17 years after initial diagnosis and showed decreased inflammatory activity in the liver. In the treatment group, the rate of se…

MaleCirrhosisAdolescentAlpha interferonHepatitis B ChronicLiver Function TestsmedicineHumansHepatitis B e AntigensSeroconversionChildmedicine.diagnostic_testbusiness.industryInterferon-alphavirus diseasesHepatitis Bmedicine.diseaseHepatitis DHepatitis Ddigestive system diseasesTreatment OutcomeHBeAgChild PreschoolPediatrics Perinatology and Child HealthImmunologyFemaleLiver functionbusinessLiver function testsFollow-Up StudiesKlinische Pädiatrie
researchProduct